Welcome to our dedicated page for United Health Pr SEC filings (Ticker: UEEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Control bleeding quickly—that’s United Health Products’ mission. Yet navigating the regulatory narrative behind that Neutralized Regenerated Cellulose patch is far harder. 300-page disclosures, dense FDA correspondence, and shifting reimbursement notes hide material facts investors need. If you’ve ever typed “How do I read United Health Products SEC filings explained simply” or searched for “United Health Products annual report 10-K simplified,” you know the struggle.
Stock Titan resolves that challenge. Our platform ingests every United Health Products quarterly earnings report 10-Q filing the moment it reaches EDGAR, then delivers AI-powered summaries that convert GAAP tables and clinical-trial updates into plain English. Need instant alerts? We flag United Health Products Form 4 insider transactions real-time so you never miss when an executive adds shares during pivotal FDA reviews. Side-by-side visualizations turn understanding United Health Products SEC documents with AI into an everyday workflow, whether you’re scanning an 8-K or reviewing “United Health Products proxy statement executive compensation.”
With comprehensive coverage of every form type—including United Health Products insider trading Form 4 transactions, United Health Products 8-K material events explained, and deep United Health Products earnings report filing analysis—Stock Titan connects documents to what drives value: clinical milestones, manufacturing scale, and cash runway. Our dashboards surface United Health Products executive stock transactions Form 4 next to operating-segment margins so you can correlate buying patterns with performance. Spend less time hunting through footnotes and more time deciding whether this hemostatic innovator deserves a place in your portfolio.
United Health Products (UEEC) filed its Q3 2025 report, showing no revenue as the company focuses on FDA approval for its CelluSTAT surgical hemostatic gauze. The quarter recorded a net loss of $285,594, and the nine-month period showed a net loss of $2,132,440.
Liquidity remains tight: cash stood at $18,376 and working capital was negative $1,963,227. Management stated there is substantial doubt about the company’s ability to continue as a going concern. Financing activity included $420,000 in new convertible notes during the nine months and 800,000 shares sold under the White Lion facility for $63,308; the CSPA commitment period ended on October 1, 2025. Shares outstanding were 258,690,253 as of November 14, 2025.
Regulatory progress remains the key driver. The FDA issued a Warning Letter related to the 2019 clinical study, and in April 2025 the FDA disapproved UHP’s IDE for a 27‑subject supplemental trial pending resolution of that letter. Subsequent to quarter end, UHP received $100,000 via a 60‑day promissory note at 13%, convertible at the holder’s election into notes maturing December 31, 2026.
FAQ
What is the current stock price of United Health Pr (UEEC)?
What is the market cap of United Health Pr (UEEC)?
